Previous 10 | Next 10 |
The decline in Cidara Therapeutics (CDTX -31.0%) that began premarket following the release of top-line data on its phase 3 antifungal candidate rezafungin has continued to widen. Shares are dropping even though the trial met FDA and EMA pre-specified primary endpoints. Earlier this...
Gainers: Galera Therapeutics (NASDAQ:GRTX) +106%. Nuverra Environmental Solutions (NYSE:NES) +33%. CPS Technologies (NASDAQ:CPSH) +24%. Terminix (NYSE:TMX) +21%. Alzamend Neuro (NASDAQ:ALZN) +17%. MIND Technology (NASDAQ:MIND) +17%. Landec Corporation (NASDAQ:LNDC) +13%. Soliton (NASDAQ:SOLY)...
Gainers: Galera Therapeutics (NASDAQ:GRTX) +116%, Alzamend Neuro (NASDAQ:ALZN) +18%, Soliton (NASDAQ:SOLY) +12%, Kiromic BioPharma (NASDAQ:KRBP) +6%, Biofrontera (NASDAQ:BFRI) +5%. Losers: Adagio Therapeutics (NASDAQ:ADGI) -78%, Adagio Th...
Adagio Therapeutics (NASDAQ:ADGI) -67% after Omicron led to 300-fold reduction in neutralizing effect in COVID-19 therapy. Aptose Biosciences (NASDAQ:APTO) -32% following ASH data on acute myeloid leukemia candidate. SeaChange International (NASDAQ:SEAC) -22%. Mesoblast (N...
Cidara Therapeutics (NASDAQ:CDTX) announces positive topline data from the Phase 3 ReSTORE trial evaluating the efficacy and safety of its once-weekly antifungal candidate rezafungin as a potential first-line treatment for candidemia and invasive candidiasis. Shares down 4.9% premar...
Trial met FDA and EMA-pre-specified primary endpoints versus daily standard of care Data to support global regulatory filings in mid-2022 Cidara to host investor conference call today, December 14th, at 8:30 a.m. EST to provide further details on the data SAN DIEGO a...
The stock market is getting smoked today, and many penny stocks haven’t been immune to this either. Shocking jobs figures reported during premarket hours added to growing concerns. On Friday, the November jobs report showed that just 210,000 jobs were added last month. This didn&...
SAN DIEGO, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced that it has been named a Top Workplace by ...
Cidara Therapeutics (NASDAQ:CDTX): Q3 GAAP EPS of -$0.37 misses by $0.02. Revenue of $7.08M (+192.6% Y/Y) beats by $4.14M. Press Release For further details see: Cidara Therapeutics EPS misses by $0.02, beats on revenue
SAN DIEGO, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today reported financial results for the third quarter ended Sept...
News, Short Squeeze, Breakout and More Instantly...
Cidara Therapeutics Inc. Company Name:
CDTX Stock Symbol:
NASDAQ Market:
Cidara Therapeutics Inc. Website:
2024-07-16 23:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious...
SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients ...